The financials
Vir Biotechnology, Inc. by the numbers
For the full year FY2025, revenue was $69M (−7.6% year on year) and net income −$438M. Its largest product in Jun 2026 was License And Collaboration at $239M, 100% of the disclosed total, well ahead of Grant at 0.0%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | n/a | $3.0M | n/a |
| Gross profit | n/a | $3.0M | n/a |
| Operating income | −$132M | −$140M | n/a |
| Net income | −$126M | −$121M | n/a |
| Diluted EPS | −$0.85 | −$0.88 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Collaboration | $239M | 100% |
| Grant | $11K | 0.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $238.9M
Grant grew -94% year on yearOther -100% year on year
Segment Latestquarter on quarteryear on year
- License And Collaboration$238.9M$238.9MQoQ -year on year ---
- Grant$11.0K$11.0KQoQ -8.3%year on year -94%-8.3%-94%
- Other$0.00$0.00QoQ -year on year -100%--100%